PMID- 30956799
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20210109
IS  - 2052-4439 (Print)
IS  - 2052-4439 (Electronic)
IS  - 2052-4439 (Linking)
VI  - 6
IP  - 1
DP  - 2019
TI  - The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated 
      minimal clinically important difference.
PG  - e000363
LID - 10.1136/bmjresp-2018-000363 [doi]
LID - e000363
AB  - INTRODUCTION: The King's Brief Interstitial Lung Disease (KBILD) is a 15-item 
      validated health-related quality of life (HRQOL) questionnaire. The method of 
      scoring the KBILD has recently changed to incorporate a logit-scale 
      transformation from one that used raw item responses, as this is potentially a 
      more linear scale. The aim of this study was to re-evaluate the KBILD minimal 
      clinically important difference (MCID) using the new logit -transformed scoring. 
      METHODS: 57 patients with interstitial lung disease (17 idiopathic pulmonary 
      fibrosis, IPF) were asked to complete the KBILD questionnaire on two occasions in 
      outpatient clinics. At the second visit, patients also completed a 15-item global 
      rating of change of health status questionnaire (GRCQ). The MCID was calculated 
      as the mean of four different methods: the change in KBILD for patients 
      indicating a small change in GRCQ, patients with a 7%-12% change in FVC, 1 SE of 
      measurement of baseline KBILD and effect size (ES) of 0.3. RESULTS: The mean (SD) 
      KBILD total score for all patients was 55.3 (15.6). 16 patients underwent a 
      therapeutic intervention. 36 patients reported a change in their condition on the 
      GRCQ; 22 deteriorated, 14 improved and 21 were unchanged. There was a significant 
      change in KBILD total score in patients reporting a change in GRCQ; mean (SD) 
      57.0 (13.6) versus 50.0 (9.7); mean difference 7.0; 95% CI of difference 3.0 to 
      11.0; p<0.01. The change in KBILD total score correlated with the GRCQ scale; 
      r=-0.49, p<0.01. The mean KBILD total score MCID was 5. The MCID of KBILD domains 
      were 6 for Psychological, 7 for Breathlessness and Activities, and 11 for Chest 
      Symptoms. CONCLUSION: The KBILD is a responsive tool for longitudinal assessment 
      of HRQOL in patients with ILD. The MCID of the KBILD total score is a 5-unit 
      change.
FAU - Sinha, Aish
AU  - Sinha A
AUID- ORCID: 0000-0001-5407-4943
AD  - Centre for Human and Applied Physiological Sciences, School of Basic and Medical 
      Biosciences, Faculty of Life Sciences and Medicine, King's College London, 
      London, UK.
AD  - Department of Respiratory Medicine, King's College Hospital, London, UK.
FAU - Patel, Amit Suresh
AU  - Patel AS
AD  - Department of Respiratory Medicine, King's College Hospital, London, UK.
FAU - Siegert, Richard J
AU  - Siegert RJ
AD  - Health and Rehabilitation Research Institute, AUT University, Auckland, New 
      Zealand.
FAU - Bajwah, Sabrina
AU  - Bajwah S
AD  - Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's 
      College London, London, UK.
FAU - Maher, Toby M
AU  - Maher TM
AUID- ORCID: 0000-0001-7192-9149
AD  - Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Renzoni, Elizabeth A
AU  - Renzoni EA
AD  - Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
FAU - Wells, Athol U
AU  - Wells AU
AD  - Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
FAU - Higginson, Irene J
AU  - Higginson IJ
AD  - Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's 
      College London, London, UK.
FAU - Birring, Surinder S
AU  - Birring SS
AD  - Centre for Human and Applied Physiological Sciences, School of Basic and Medical 
      Biosciences, Faculty of Life Sciences and Medicine, King's College London, 
      London, UK.
AD  - Department of Respiratory Medicine, King's College Hospital, London, UK.
LA  - eng
GR  - 20719/VAC_/Versus Arthritis/United Kingdom
GR  - PB-PG-0712-28073/DH_/Department of Health/United Kingdom
GR  - PB-PG-0808-17311/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20190218
PL  - England
TA  - BMJ Open Respir Res
JT  - BMJ open respiratory research
JID - 101638061
MH  - Aged
MH  - Female
MH  - Humans
MH  - Lung Diseases, Interstitial/complications/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - *Minimal Clinically Important Difference
MH  - *Quality of Life
MH  - Surveys and Questionnaires
PMC - PMC6424243
OTO - NOTNLM
OT  - global rating of change questionnaire
OT  - health related quality of life
OT  - interstitial lung disease
OT  - king's brief Interstitial lung disease questionnaire
OT  - minimal clinically important difference
COIS- Competing interests: TMM has, via his institution, received industry-academic 
      funding from GlaxoSmithKline R&D and UCB and has received consultancy or 
      speaker's fees from Apellis, Astra Zeneca, Bayer, Biogen Idec, Boehringer 
      Ingelheim, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, 
      Samumed and UCB.
EDAT- 2019/04/09 06:00
MHDA- 2019/04/09 06:01
PMCR- 2019/02/18
CRDT- 2019/04/09 06:00
PHST- 2018/10/02 00:00 [received]
PHST- 2018/12/27 00:00 [revised]
PHST- 2018/12/28 00:00 [accepted]
PHST- 2019/04/09 06:00 [entrez]
PHST- 2019/04/09 06:00 [pubmed]
PHST- 2019/04/09 06:01 [medline]
PHST- 2019/02/18 00:00 [pmc-release]
AID - bmjresp-2018-000363 [pii]
AID - 10.1136/bmjresp-2018-000363 [doi]
PST - epublish
SO  - BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. 
      eCollection 2019.